Rituximab therapy for lupus nephritis: A meta-analysis

LEI SHEN1*, XIANGYING LIU2*, CI SUN3, GUOYUAN LU1, LING ZHOU1 and JIANZHONG LI1

1Department of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006; 2Department of Nephrology, Suzhou Ninth People's Hospital, Suzhou, Jiangsu 215299; 3Department of Nephrology, The Second Affiliated Hospital of Soochow University (The General Hospital of Nuclear Industry, The Sino-France Friendship Hospital), Suzhou, Jiangsu 215004, P.R. China

Received March 23, 2021; Accepted July 20, 2021

DOI: 10.3892/wasj.2021.119

Abstract. The aim of the present study was to assess the clinical efficacy and safety of rituximab (RTX) therapy in the treatment of lupus nephritis by performing a meta-analysis. For this purpose, the PubMed, Embase, Cochrane Library, Chinese Biomedical Literature, China National Knowledge Infrastructure, VIP Information and WAFANG databases were used to identify the eligible studies from January, 2000 to February, 2020. STATA16.0 and Review Manager Version 5.3 software were applied to pool the data. From the results of this search, 37 studies (30 case series and seven controlled trials) involving 1,273 patients were included. In the case series studies, the total remission (TR) rate was 81.9% (95% CI, 73.7‑88.8%) and the complete remission (CR) rate was 46.6% (95% CI, 36.4‑57.1%). Following treatment with RTX, the systemic lupus erythematosus disease activity index (SLEDAI) of patients with lupus nephritis decreased significantly [mean difference (MD), -8.91; 95% CI, -14.10 to -3.72, P<0.01]. The level of proteinuria also decreased significantly [standardized mean difference (SMD), -1.05; 95% CI, -1.28 to -0.83, P<0.01]. On the contrary, the level of serum albumin increased significantly (MD, 0.54; 95% CI, 0.22‑0.86; P<0.01). There was no difference in the relative risks of the adverse events between the two groups (OR, 0.37; P>0.05). On the whole, the findings of the present study demonstrate that RTX exhibits favorable clinical efficacy in the treatment of lupus nephritis, which can significantly reduce the level of proteinuria and SLEDAI, and increase the level of serum albumin. Compared with traditional immunosuppressive therapy (corticosteroids + cyclophosphamide and/or mycophenolate), RTX was more effective in the treatment of lupus nephritis. Additionally, rituximab exhibited good safety.

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multi-organ damage. Kidney involvement occurs in up to 60% of patients with SLE (1,2). Owing to treatment with corticosteroids and immunosuppressive therapy, the prognosis of patients with lupus nephritis (LN) has markedly improved; however, a large number of patients continue to develop irreversible kidney damage and end-stage renal disease. Therefore, the identification of novel, more effective therapeutic methods with more favorable safety profiles are urgently required.

Hyper-reactive B lymphocytes play a central role in the pathogenesis of LN. The abnormal activation of B lymphocytes produces a large number of pathogenic autoantibodies, which causes disorders in the cellular and humoral immunity and leads to tissue damage. Therefore, B-lymphocyte depletion (BlyD) (3) can result in the significant clinical remission of LN. Another study reported that B lymphocyte stimulators exist in the kidney tubulointerstitium, which can induce pathogenic B lymphocyte migration, leading to sustained kidney injury. However, rituximab (RTX) can deplete B lymphocytes in the kidney tubulointerstitium continuously and achieve BlyD (4).

RTX is a chimeric antibody which binds specifically to the B-cell surface antigen, CD20, an integral membrane protein, which is expressed immature and mature B lymphocytes, but it is not found in early B-cell precursors or plasma cells (5). RTX exerts its effect through three pathways: By binding to Fc receptor and mediating cell killing through antibody-dependent cellular toxicity, by binding C1q and activating complement-dependent cytotoxicity and finally, by stimulating the apoptotic pathway (3).

Key words: rituximab, lupus nephritis, systemic lupus erythematosus, B lymphocytes, CD20

Correspondence to: Dr Ci Sun, Department of Nephrology, The Second Affiliated Hospital of Soochow University (The General Hospital of Nuclear Industry, The Sino-France Friendship Hospital), 1055 Sanxiang Road, Suzhou, Jiangsu 215004, P.R. China E-mail: 78796940@qq.com

*Contributed equally
RTX was the first approved agent for the treatment of relapsed or refractory lymphoma. It has subsequently been used in various autoimmune diseases, including LN (6,7). However, the majority of the studies on RTX in LN are case reports or small clinical studies (as demonstrated below in the Results section). Thus, the present study aimed to assess the clinical efficacy and safety of RTX as a novel immunosuppressive treatment for LN by performing a meta-analysis of the available literature.

Data and methods


Inclusion and exclusion criteria. The following inclusion criteria were used: i) Case series (retrospective case series and prospective case series) or controlled trials [randomized controlled trials (RCTs) and non-RCTs] regarding RTX therapy in patients with LN; ii) availability of data on therapeutic efficacy and safety; iii) availability of data on urinary protein, serum albumin and activity index (SLEDAI) prior to and following treatment; and iv) enrolled patients with a diagnosis of LN disease based on the American College of Rheumatology criteria. The following exclusion criteria were used: i) Abstracts, reviews, case reports and editorials; ii) animal experiments; iii) inability to extract complete data from the literature; and iv) duplicate reports from the same study.

Data extraction. In total, two investigators performed the screening of the abstracts and identified duplicates by reviewing full articles, determining their eligibility and extracting data independently. A custom Excel sheet was used to collect all relevant data based on the surname of the first author, publication year, case number, age, sex, intervention and outcome characteristics.

Quality evaluation. The quality assessment tool of the Institute of Health Economics (IHE) (https://ihe.ac.bd/) was used in case series studies. The quality of the results was considered acceptable if the score was >14. The quality of non-randomized controlled studies was assessed according to the methodological index for non-randomized studies (MINORS) (8) tool. The quality was considered acceptable if the score was >13. The JADAD quality scale (9) was used to assess the quality of randomized controlled studies. A score <3 was considered low quality, while a score with a range of 4-7 was considered high quality.

Statistical analysis. STATA16.0 and Review Manager Version 5.3 were used to pool the data. The remission rate of the case series was pooled by STATA16.0. Additional data analysis was performed by Review Manager Version 5.3. Homogeneous studies (I²<50%) were examined by a fixed-effects model to estimate the combined effect. Heterogeneous studies (I²>50%) were examined by a random-effects model. P<0.05 was considered to indicate a statistically significant difference.

The present study was mainly divided into two parts. The first part was a case series analysis, including prospective and retrospective case studies. The following parameters were analyzed: Total remission rate (TR; complete remission plus partial remission), complete remission rate (CR), proteinuria and SLEDAI. The second part was controlled trial analysis, involving the comparison of the parameters TR, CR, proteinuria, serum albumin and SLEDAI between the RTX and the control groups.

Results

Characteristics of the included studies. A total of 1,593 publications were searched in total, of which 36 studies involving 1,280 patients were included. These studies comprised 29 case series (10-38) and seven controlled trials (39-45). In total, six trials were published in Chinese, whereas 30 trials were published in English. The patients examined in four trials were children, whereas the remaining 32 trials included adults. The details of these trials are presented in Tables I and SI.

Quality evaluation of the literature. A total of 29 case series were evaluated by the IHE quality assessment tool, all of which met >14 criteria and were considered acceptable (10-38). In total, five non-randomized trials were evaluated by the MINORS quality assessment tool, all of which scored >13 and were considered acceptable (39-43). Moreover, two randomized trials were evaluated by the JADAD quality scale tool (44,45). The score for the study by Rovin et al (44) was 5, whereas the score for the study of Zhang et al (45) was 4. Both of them were considered high quality.

Case series with LN. The results of the meta-analysis indicated that 28 studies involving 641 patients with LN analyzed clinical remission as an outcome (10-37). The TR was 81.9% (95% CI, 73.7-88.8%; P<0.05; Fig. 1), whereas the CR was 46.6% (95% CI, 36.4-57.1%; P>0.05; Fig. 2).

In total, three case series reported changes in the SLEDAI of patients with LN (31,35,36). The results indicated that following treatment of the patients with RTX, the SLEDAI decreased significantly [mean difference (MD), -8.91; 95% CI, -14.10 to -3.72; P<0.01; Fig. 3].

In total, six studies reported the levels of proteinuria prior to and following RTX treatment (13,20,23,25,30,34). The data were analyzed and it was shown that the levels of proteinuria in patients with LN were significantly reduced following treatment with RTX [standardized mean difference (SMD), -1.05; 95% CI, -1.28 to -0.83; P<0.01; Fig. 4].
Table I. Characteristics of the controlled trials included in the present meta-analysis.

<table>
<thead>
<tr>
<th>Author/(Refs.), year</th>
<th>n/nc</th>
<th>Age (years) (R/C)</th>
<th>Male/female</th>
<th>Tm</th>
<th>Cs dose</th>
<th>Treatment protocol</th>
</tr>
</thead>
</table>
| Goswami et al (40), 2019 | 22/200 | 26.32±9.04/26.07±9.24 | N/A | 6 | N/A | R: RTX: 1.9±0.25 g  
C: MMF: 1.5‑3 g/day (61 pt); CYC: 500 mg*6 (26 pt); CYC: 750‑1,200 mg*6 (113 pt) |
| Li et al (42), 2014 | 12/15 | 17‑63/15‑50 | 5/22 | 3 | MTP 500 mg/3 days, oral prednisolone 0.6 mg/kg daily for 4 weeks, then progressively tapered | R: RTX: 375 mg/m² QW*4, 2 weeks apart  
C: CYC: 0.8 g*2, 2 weeks apart |
| Wu (43), 2019 | 32/32 | 41.1±2.0/41.6±2.2 | 19/45 | N/A | Oral prednisolone 0.6 mg/kg daily for 4 weeks, then progressively tapered | R: RTX: 375 mg/m² QW*4, 2 weeks apart  
C: MMF: 1.0 g b.i.d. |
| Basu et al (39), 2017 | 17/27 | 8.4±4.6/8.1±3.2 | 23/21 | 36 | Oral prednisolone 2 mg/kg daily for 1 month, then progressively tapered | R: RTX: 375 mg/m² QW*2  
C: MMF: 1.2g/m²/day, CYC: 500 mg/m²*6, 2 weeks apart |
| Rovin et al (44), 2012 | 72/72 | 31.8±9.6/29.4±9.3 | 12/130 | 13 | Oral prednisolone 0.75 mg/kg daily for 16 days, then progressively tapered | R: 1 g*4, on days 1, 15, 168, 182; MMF: 1.5‑3 g/day  
C: MMF: 1.5-3 g/day |
| Moroni et al (41), 2014 | 17/37 | 31.1±9.5/31.0±8.3 | 7/47 | 12 | Oral prednisolone 0.5‑0.75 mg/kg daily for 4 weeks, then progressively tapered | R: 1 g*2, on days 1 and 18  
C: MMF: 2-2.5 g/day; CYC: 0.5 g*6, 4 weeks apart |
| Zhang et al (45), 2015 | 42/42 | 38.7±6.2/39.1±7.0 | 24/60 | 12 | MTP 500 mg/3 days, oral prednisolone 1 mg/kg daily for 8 weeks then progressively tapered | R: RTX: 375 mg/m² QW*2; CYC: 0.8 g*2, 2 weeks apart  
C: CYC: 0.8 g*12, 4 weeks apart |

nr, number of patients in the RTX group; nc, number of patients in the control group; R, rituximab group; C, control group; Cs, corticosteroids; RTX, rituximab; MMF, mycophenolate mofetil; CYC, cyclophosphamide; QW, once a week; *4, used for 4 times; *2, used for 2 times; *6, used for 6 times.
In total, three case series reported serum albumin levels (13, 20, 30). The results indicated that following treatment of the patients with RTX, the levels of serum albumin were significantly increased (MD, 6.44; 95% CI, 4.42-8.45; P<0.01; Fig. 5).

Controlled trials with LN. A total of seven controlled trials were included in the statistical analysis, involving a total of 639 patients (RTX group, 214 cases; control group, 425 cases). The treatment regimen for the RTX group was single-drug RTX or corticosteroids plus RTX or corticosteroids plus RTX plus cyclophosphamide (CYC)/mycophenolate mofetil (MMF), while the control group was treated with routine corticosteroids plus CYC, CYC plus MMF or corticosteroids plus CYC plus MMF.

TR and CR were reported in seven control trials (39-45). Following the meta-analysis, it was found that both the TR and CR were significantly higher in the RTX group than in the control group [TR: Odds ratio (OR), 2.48; 95% CI, 1.58-3.89; P<0.01; Fig. 6; CR: OR, 2.29; 95% CI, 1.17-4.49; P<0.05; Fig. 7].

In total, five studies compared the SLEDAI (39, 41-43, 45). It was found that its levels were lower in the RTX group than those of the control group. The results were statistically significant (MD, -3.84, 95% CI, -5.99-1.69; P<0.01; Fig. 8).

A total of five studies that examined proteinuria were included in the analysis (40-43, 45). The results indicated that the levels of proteinuria in the RTX group were lower than those noted in the control group. The differences were statistically significant (MD, -1.24; 95% CI, -2.39-0.09; P<0.05; Fig. 9).

In total, three studies compared plasma albumin levels and the data indicated that the serum albumin levels in the RTX group were significantly higher than those in the control group (MD, 0.54; 95% CI, 0.22-0.86; P<0.01; Fig. 10) (41,42,45).

Adverse events. A total of 16 case series involving 188 patients reported adverse reactions following RTX treatment, including 21 (11.2%) patients who developed infusion reactions (10-22,30,36,38). A total of 65 (34.6%) patients developed mild infections, mainly in the respiratory and urinary system and recovered following treatment. Furthermore, 4 (2%) patients developed severe infection following RTX treatment and 1 patient died of severe infection; granulocytopenia occurred in 7 (3.7%) patients during treatment; only 1 (0.5%) of the patients developed skin photosensitive reaction following treatment.

A total of four controlled trials reported adverse reactions (39,40,42,44). The data reported in these studies were compared between the RTX and the control groups. No significant differences were noted (OR, 0.37; P>0.05; Fig. 11).

Discussion

LN is a severe manifestation of SLE. The treatment of LN can be adjusted by reducing the steroid dose, optimizing...
CYC protocols and introducing new drugs, such as MMF and tacrolimus. The European League against Rheumatism recommendations suggest that MMF and low-dose CYC are the treatments of choice for the induction of remission and should

**Figure 2.** Complete remission rate in patients treated with rituximab in the case series trials.

**Figure 3.** Results of the meta-analysis of the systemic lupus erythematosus disease activity index in patients treated with rituximab in the case series trials.

**Figure 4.** Results of the meta-analysis of proteinuria in patients treated with rituximab in the case series trials.
be followed by a maintenance therapy with MMF, azathioprine or calcineurin inhibitors (46). However, Tektonidou et al (47) demonstrated that the incidence of end-stage renal disease has plateaued at ~10% compared with the increase noted in the 2000s.

The pathogenesis of SLE is complex. It is widely accepted that the abnormal activation of B lymphocytes and the production of a large number of autoantibodies causes immune function disorders (48,49). A previous study reported that among 119 patients with LN, ~52.1% experienced B lymphocyte infiltration in their kidney tissues. The levels of serum creatinine and urea, which are considered indices of kidney tissue activity and chronicity, were significantly increased in patients with B lymphocyte infiltration compared with those without B lymphocyte infiltration (50). An additional study indicated significant improvements in the clinical
outcomes of patients with LN following B lymphocyte deple-
tion therapy (51). The aforementioned data indicated that B
lymphocytes played an important role in the incidence and
development of LN. B lymphocytes produce antibodies, which
in turn form antigen-antibody complexes. These structures
deposit in kidney tissues and induce T lymphocyte activation,
in turn is involved in immuno-inflammatory responses.

RTX is a chimeric monoclonal antibody, which specifi-
cally targets the CD20 antigen on the surface of B cells.

Anolik et al (52) reported that RTX therapy regulated the dysfunction of B lymphocytes and reduced the number of self-reactive memory B lymphocytes for 1 year. Moroni et al (41) examined 54 patients with active LN, which were treated with RTX, MMF or CYC for 12 months; their complete remission rates were 70.6, 52.9 and 65%, respectively, whereas their partial remission rates were 29.4, 41.2 and 25%, respectively. It is worth noting that the patients treated with RTX exhibited more severe LN. However, the majority of the studies regarding the use of RTX for LN were case reports or low-sample size clinical studies. The present meta-analysis assessed the clinical efficacy and safety of RTX for the treat-
ment of LN.

Proteinuria is an independent risk factor for kidney progression. The analysis of six case series and five controlled

trials demonstrated that proteinuria markers were signifi-
cantly decreased following RTX treatment, suggesting that
the latter was more effective in treating LN compared with
other conventional therapies. RTX exerted increased protec-
tive effects against kidney injury compared with traditional
immune-suppressants (hormones and/or CYC and MMF),
which were consistent with the results from the study by
Alshaiki et al (53). Hypoalbuminemia is another manifestation
of LN, which is mainly caused by the increased filtration of
proteins from the glomeruli compared with their reabsorption
and synthesis in the kidney and liver, respectively. The present
meta-analysis indicated that treatment of the patients with
RTX resulted in a significant increase of their serum albumin
levels compared with those of the control group, suggesting
that RTX was an effective therapeutic agent for LN.

SLEDAI is a direct method to assess the activity and
severity of SLE (54). The present analysis included three
case series and five control trials. A significant decrease in
SLEDAI was noted following RTX treatment, suggesting that
this compound exhibited favorable clinical efficacy in the
treatment for LN.

TR and CR varied slightly among different studies, since
they were dependent on several factors, such as proteinuria,
serum albumin, creatinine and SLEDAI. A total of 30 case
series were analyzed and the data indicated that following
RTX treatment, the parameters TR and the CR were 81.9 and 46.6%, respectively, which was consistent with the results of the study by Zhong et al. (55). In addition, seven controlled trials were analyzed and the results indicated that both TR and CR were significantly higher than those of the control group, suggesting that RTX was more effective in the treatment of LN compared with traditional immune-suppressants.

B-lymphocyte depletion can result in significant clinical remission of LN. An enhanced B-cell depletion in LN may result in a more homogenous B-cell depletion profile across participants and increased efficacy in the treatment of LN. The specific correlation analysis between the remission rate of LN and the degree of B-cell depletion following RTX treatment was not shown in the present study due to limitations of data extraction, different ethnic or racial backgrounds. On the other hand, it was suggested that RTX alone may not deplete B cells sufficiently for the perturbations of LN (56).

The adverse events of RTX mainly included the following: i) Infusion reaction, which occurred often within 1-2 h following the first intravenous infusion and could be prevented by the prophylactic use of antihistamines or hormones; ii) infection, which may have been associated with the apparent inhibition of B lymphocytes by RTX and the combined use of corticosteroids, CYC, MMF, cyclosporine and other immunosuppressive agents; iii) granulocytopenia, which may be associated with myelosuppression induction by RTX; and iv) photosensitive reactions, which exhibited very low incidence. The membranes or organelles of epidermal cells were damaged by RTX, resulting in adverse events following exposure in ultraviolet radiation. Although RTX treatment was associated with the aforementioned adverse reactions, no significant differences were noted compared with traditional immunosuppressive agents, suggesting that this compound exhibited optimal safety.

The present study has certain limitations which should be mentioned: i) The number of patients included in some studies analyzed was small and the observation time was not consistent across different studies, resulting in a certain degree of error in the estimation of the remission rate; ii) the quality of some included results was low; iii) reports on the recurrence of the disease following RTX treatment for a specific period of time were limited and could not provide sufficient data for statistical comparisons; and iv) publication bias was not included for the selected studies. Therefore, further prospective, larger sample size and high-quality RCT studies are required to further clarify the application timing, optimal usage and dosage, prevention of recurrence and treatment strategies following recurrence. These additional factors may provide guidance for the clinical treatment of LN.

In conclusion, from the present meta-analysis, it was found that RTX exhibited favorable clinical efficacy in the treatment of LN. RTX was more effective in the treatment of LN compared with traditional immunosuppressive therapy (corticosteroids + CYC and/or MMF). In addition, RTX exhibited optimal safety without adverse reactions, such as liver and gonadal damage.

Acknowledgements

Not applicable.

Funding

The present study was supported by a grant from the Project of Healthy in Jiangsu Province (no. SS2019055).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

LS contributed to the conception, design and modification of the study. CS and XL reviewed the articles, extracted the data and organized the database search. XL performed the statistical analysis. CS wrote the first draft of the manuscript. GL guided and assisted in the statistical analysis. LZ and JL also contributed to the conception and design of the study. LS, LZ and JL confirm the authenticity of all the data. All authors contributed to manuscript revision, read, and approved the submitted version.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


